VENLAFAXINE BESYLATE Drug Patent Profile

Which patents cover Venlafaxine Besylate, and what generic alternatives are available?

Venlafaxine Besylate is a drug marketed by Almatica and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in VENLAFAXINE BESYLATE is venlafaxine besylate. There are seventy-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the venlafaxine besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Venlafaxine Besylate

A generic version of VENLAFAXINE BESYLATE was approved as venlafaxine besylate by ALMATICA on June 29^th, 2022.

Summary for VENLAFAXINE BESYLATE

US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	1
Patent Applications:	10
DailyMed Link:	VENLAFAXINE BESYLATE at DailyMed

Recent Clinical Trials for VENLAFAXINE BESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alphacait, LLC	Phase 2
Haining Health-Coming Biotech Co., Ltd.	Phase 2

See all VENLAFAXINE BESYLATE clinical trials

Pharmacology for VENLAFAXINE BESYLATE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VENLAFAXINE BESYLATE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for VENLAFAXINE BESYLATE

VENLAFAXINE BESYLATE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	VENLAFAXINE BESYLATE	venlafaxine besylate	TABLET, EXTENDED RELEASE;ORAL	215429-001	Jun 29, 2022		RX	Yes	Yes			Y

Expired US Patents for VENLAFAXINE BESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almatica	VENLAFAXINE BESYLATE	venlafaxine besylate	TABLET, EXTENDED RELEASE;ORAL	215429-001	Jun 29, 2022

Premature patent expiration for: VENLAFAXINE BESYLATE

Expiration due to failure to pay maintenance fee

Patent Number	Tradename	Expiration Date
	VENLAFAXINE BESYLATE

International Patents for VENLAFAXINE BESYLATE

See the table below for patents covering VENLAFAXINE BESYLATE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1485344	BESYLATE DE VENLAFAXINE (VENLAFAXINE BESYLATE)
Argentina	039163	BESILATO DE VENLAFAXINA
South Africa	200406461	Venlafaxine besylate
Australia	2003221535	VENLAFAXINE BESYLATE
World Intellectual Property Organization (WIPO)	03082804

Market Dynamics and Financial Trajectory for Venlafaxine Besylate

Last updated: January 23, 2026

Executive Summary

Venlafaxine besylate, marketed predominantly as Effexor and Effexor XR, is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved primarily for major depressive disorder, generalized anxiety disorder, and other related conditions. Its global market landscape is characterized by high competition, patent expiration, evolving prescribing guidelines, and increasing penetration into emerging markets. This report delineates key trends, revenue forecasts, patent insights, regulatory landscape, and competitive dynamics impacting venlafaxine besylate from a financial and market perspective.

---

Market Overview

Market Size and Growth Trajectory

Parameter	2022 Estimate	2028 Forecast	CAGR (2023–2028)
Global antidepressant market value (USD billion)	$15.4 billion	$20.8 billion	6.4%
Venlafaxine segment share (%)	~12%	~10%	-1.2% (decline)
Estimated global revenues (USD million)	$1.85 billion	$2.08 billion	3.2%

Source: IQVIA Institute, 2022; Grand View Research, 2023.

Key Market Drivers

• Increasing prevalence of depression and anxiety disorders globally.
• Rising awareness and destigmatization of mental health.
• Expanding approval for use in pediatric and chronic pain indications.
• Growing generic competition (post-patent expiration).

Key Market Constraints

• Patent expiry of Effexor XR in multiple territories (notably US in 2017).
• Generic erosion of market share post-patent expiry.
• Stringent regulatory requirements impacting marketing.
• Competition from newer antidepressants (e.g., vortioxetine, vilazodone).

---

Patent and Regulatory Status

Key Patent Milestone	Status	Impact
Original patent (U.S.)	Filed: 1990; Expired: 2017	Rapid generic entry post-expiry
Pending patents for secondary formulations	Pending/IP protection ongoing	Potential new formulations or delivery methods
Regulatory approvals in key markets	Approved globally; some markets ending exclusivity	Market entry barriers for generics

Note: Multiple US and international patents protected the original formulation until expiration in 2017, impacting market exclusivity.

---

Commercial Competition and Market Share

Key Competitors

Brand Name	Generic Status	Indications	Market Position
Effexor XR	Patent expired (2017)	Major depressive disorder, GAD	Leading brand until patent expiry
Desvenlafaxine (Pristiq)	Patent protected	Similar indications	Rising share post-effexor expiry
Duloxetine (Cymbalta)	Patent expired (2013)	Depression, neuropathy	Significant competitor
Generic venlafaxine	Available (post-patent)	Same indications	Dominant post-patent period

Market Share Dynamics

Period	Brand Names Dominance	Estimated Market Share (%)
Pre-2017 (patent protected)	Effexor XR	~80%
Post-2017 (generic entry)	Generics, Desvenlafaxine	Effexor XR (~40%), Generics (~60%)

Note: Exact market shares vary by country.

---

Financial Trajectory Analysis

Revenue Trends Post-Patent Expiry

Year	Approximate Revenue (USD million)	Comments
2017	$1,200	Peak prior to patent expiry
2018	$600	Marked decline due to generic entry
2020	$350	Continued erosion, influence of generics
2022	$360	Market stabilization with generics
2028	$400–$500	Potential stabilization, growth via new formulations, emerging markets

Key Market Segments

Segment	Percentage of Revenue (2022)	Trends
Generic sales	70%	Post-patent erosion
Branded formulations (Effexor XR)	20%	Niche, high-value markets, specialty indications
New formulations / Line extensions	10%	Limited, emerging in personalized medicine

---

Emerging Trends Influencing Market Dynamics

1. Generic Competition and Price Erosion

The expiration of US and EU patents in 2017 has caused a precipitous drop in branded sales. Generics now dominate, leading to substantial price reductions (up to 80% in some markets). This shift has compelled manufacturers to pursue line extensions, novel delivery systems, or combination formulations to restore revenue.

2. Regulatory Approvals and Indications Expansion

Recent approvals for pediatric depression, treatment-resistant cases, and adjunctive therapy have opened new revenue streams. Regulatory agencies like FDA and EMA are increasingly supportive of expanded uses, influencing market dynamics positively.

3. Geographic Expansion in Emerging Markets

Growth potentials exist in Asia-Pacific, Latin America, and the Middle East, where antidepressant treatment rates are rising, driven by mental health policy reforms and increased healthcare access.

---

Strategic Actions and Market Outlook

Product Lifecycle Management

• Development of fixed-dose combinations.
• Introduction of long-acting formulations or new delivery systems (e.g., transdermal patches).
• Focus on niche indications to sustain premium pricing.

Mergers, Acquisitions, and Collaborations

• Companies are acquiring or partnering to expand pipelines, especially in biosimilar and line extension domains.

Pricing and Reimbursement Strategies

• Emphasis on value-based pricing driven by real-world efficacy data.
• Engagement with payers to ensure formulary inclusion.

---

Comparative Analysis: Venlafaxine vs. Competitors

Parameter	Venlafaxine (Effexor XR)	Duloxetine	Desvenlafaxine	Vortioxetine
Patent Status	Expired (2017)	Expired (2013)	Patented	Patented
US Market Revenue (2022)	~$0.36 billion	$0.63 billion	Data not available	Not indicated as a direct competitor
Main Indications	Depression, GAD	Depression, neuropathy	Depression	Depression, cognitive impairment
Number of Approved Formulations	Single (XR)	Multiple	Single	Multiple

---

Key Takeaways

1. Patent expiry has significantly shifted revenue dynamics, with generics now dominating globally and forcing innovation to maintain profitability.
2. Market growth is modest (3–4%) driven by emerging markets and expanding indications, but still faces headwinds from newer therapeutic options and regulatory constraints.
3. Developing novel formulations, exploring new indications, and geographic expansion are essential strategies to restore or enhance financial returns.
4. Pricing pressures and reimbursement challenges necessitate value demonstration through clinical evidence.
5. Competitive landscape has become highly commoditized, requiring differentiated offerings for sustained market presence.

---

FAQs

Q1: What is the current patent status of venlafaxine besylate?

A1: The original patent expired in the United States in 2017, leading to widespread generic availability. Pending patents for secondary formulations may still offer exclusivity in certain markets.

Q2: How has patent expiration impacted the market share of venlafaxine?

A2: The brand Effexor XR's market share dropped significantly from approximately 80% pre-2017 to around 40% or less, with generics capturing the majority of prescriptions.

Q3: What are the main competitive threats to venlafaxine?

A3: Key threats include newer SNRI and SSRI alternatives like duloxetine and vortioxetine, better-tolerated medications, and innovative delivery systems.

Q4: Are there opportunities for branded formulations post-patent expiry?

A4: Yes. Strategies include developing line extensions, combination therapies, or formulations with improved patient compliance, as well as targeting underserved indications or markets.

Q5: Which emerging markets offer the greatest potential for venlafaxine growth?

A5: Asia-Pacific (especially China and India), Latin America, and parts of the Middle East represent significant opportunities due to increasing mental health awareness and evolving healthcare infrastructure.

---

References

1. IQVIA Institute. (2022). Global Psychotropic Market Analysis.
2. Grand View Research. (2023). Antidepressant Market Size, Share & Trends.
3. US Patent Office. (2017). Patent expiration analysis for Effexor XR.
4. FDA. (2022). Approved indications for venlafaxine.
5. MarketWatch. (2023). Post-patent generic trends in antidepressants.

---

Disclaimer: Market forecasts and data are indicative and subject to change based on regulatory actions, patent litigation, and clinical breakthroughs.